FDA Expands Ilumya Approval for Psoriatic Arthritis Treatment

The U.S. Food and Drug Administration (FDA) has approved Sun Pharma's Ilumya (tildrakizumab-asmn) for treating active psoriatic arthritis in adults. This decision broadens the application of the interleukin-23 (IL-23) inhibitor, which was previously approved in 2018 for moderate-to-severe plaque psoriasis. The expanded label introduces a new treatment option for rheumatology patients.